Identification of Agonistic Autoantibodies Associated with Humoral Kidney Rejection
AssigneeMax-Delbrueck-Centrum Fuer Molekulare Medizin
InventorGerd Wallukat
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for detecting autoantibodies associated with humoral kidney rejection, which recognize extracellular structures of G protein-coupled receptors, and to the use of peptides, which comprise these loops or fragments thereof, for treating humoral kidney rejection.
Claims20
1-35. (canceled)
Method for detecting autoantibodies associated with humoral kidney rejection, comprising the following steps:
- a) Bringing bodily fluid into contact with a denaturing agent,
- b) Bringing the precipitated fraction into contact with a peptide, particularly one comprising biotin, which comprises a partial sequence of the first and/or second loop of the receptor, whereby a mixture is formed,
- c) Incubating the mixture with a carrier coated with avidin or streptavidin,
- d) Washing the materials of the carrier,
- e) Incubating the carrier with anti-IgG antibody subclasses, whereby the anti-IgG antibody is marked, and
- f) Carrying out an enzyme reaction or color reaction.
Peptide selected from the group consisting of AFHYESQ and ENTNIT, for use as a medicinal active substance in the treatment of humoral kidney rejection.
Pharmaceutical composition for use in the treatment of humoral kidney rejection, comprising a peptide selected from the group consisting of AFHYESQ and ENTNIT and/or a recognition molecule directed against the peptide.
Kit comprising a peptide for use in the treatment of humoral kidney rejection selected from the group consisting of AFHYESQ and ENTNIT, a recognition molecule directed against the peptide, and/or a pharmaceutical composition comprising the peptide and/or the recognition molecule.
Chromatography device comprising peptides associated with humoral kidney rejection selected from the group consisting of AFHYESQ and ENTNIT, and/or recognition molecules directed against the peptide.
Method for treating humoral kidney rejection by means of binding and/or removing antibodies by means of peptidesselected from the group consisting of AFHYESQ and ENTNIT, bound to a solid phase.
Method for the prophylaxis, diagnosis, therapy, monitoring the progression as well as follow-up treatment of humoral kidney rejection, comprising the step of using one or more chosen from the following:
- (a) Peptide selected from the group consisting of AFHYESQ and ENTNIT (b) a recognition molecule directed against said peptide (c) a pharmaceutical composition comprising said peptide and said recognition molecule (d) a kit comprising one of said peptide, said recognition molecule or said pharmaceutical composition, optionally with instructions for combining the contents of the kit and/or for making available a formulation and (e) a chromatography device comprising said peptide or said recognition molecule.
Method for the production of a medication for the treatment of humoral kidney rejection, comprising the step of using one or more chosen from the following (a) Peptide selected from the group consisting of AFHYESQ and ENTNIT (b) a recognition molecule directed against said peptide (c) a pharmaceutical composition comprising said peptide and said recognition molecule (d) a kit comprising one of said peptide, said recognition molecule or said pharmaceutical composition, optionally with instructions for combining the contents of the kit and/or for making available a formulation and (e) a chromatography device comprising said peptide or said recognition molecule.
Method for screening medications for the treatment of humoral kidney rejection, comprising the step of one or more chosen from the following (a) Peptide selected from the group consisting of AFHYESQ and ENTNIT (b) a recognition molecule directed against said peptide (c) a pharmaceutical composition comprising said peptide and said recognition molecule (d) a kit comprising one of said peptide, said recognition molecule or said pharmaceutical composition, optionally with instructions for combining the contents of the kit and/or for making available a formulation and (e) a chromatography device comprising said peptide or said recognition molecule.
Method for detecting, binding, complexing or neutralizing of autoantibodies associated with humoral kidney rejection, directed against angiotensin II AT1 receptor, comprising the step of using a peptide selected from the group consisting of AFHYESQ and ENTNIT.
Dependencies are inferred from the claim text.